

## Research Article

# Polyphenol metabolites from colonic microbiota exert anti-inflammatory activity on different inflammation models

Mar Larrosa<sup>1</sup>, Cristina Luceri<sup>1</sup>, Elisa Vivoli<sup>1</sup>, Chiara Pagliuca<sup>2</sup>, Maura Lodovici<sup>1</sup>,  
Gloriano Moneti<sup>3</sup> and Piero Dolara<sup>1</sup>

<sup>1</sup> Department of Pharmacology, University of Florence, Florence, Italy

<sup>2</sup> Department of Organic Chemistry, Via della Lastruccia 13, Sesto Fiorentino Florence, Italy

<sup>3</sup> Interdepartmental Centre of Mass Spectrometry, University of Florence, Florence, Italy

The polyphenols in fruits and vegetables may be partly responsible for the health-promoting effects attributed to fruit and vegetable intake. Although their properties have been relatively well studied, the activity of their metabolites, produced after ingestion, has been poorly investigated. Thus, the aim of this work was to study the potential anti-inflammatory effect of 18 polyphenol metabolites, derived from colon microbiota. They were screened by measuring prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) production by CCD-18 colon fibroblast cells stimulated with IL-1 $\beta$ . Metabolites that inhibited more than 50% PGE<sub>2</sub> production were hydrocaffeic (HCAF), dihydroxyphenyl acetic (dOHPA), and hydroferulic acid (HFER), that subsequently were tested with the writhing and paw pressure test in rodents where all three compounds showed an anti-inflammatory effect. The effect of HCAF administered orally (50 mg/kg) was also tested in the dextran sodium sulfate (DSS)-induced colitis model. Weight loss and fecal water content were more pronounced in DSS rats than in DSS-HCAF treated rats. HCAF treatment diminished the expression of the cytokines IL-1 $\beta$ , IL-8, and TNF- $\alpha$ , reduced malonyldialdehyde (MDA) levels and oxidative DNA damage (measured as 8-oxo-2'-deoxyguanosine levels) in distal colon mucosa. These results indicate that HCAF, dOHPA, and HFER have anti-inflammatory activity *in vitro* and *in vivo*.

**Keywords:** Hydrocaffeic acid / Inflammation / MDA / 8-oxodG / Polyphenol metabolite

Received: September 26, 2008; revised: November 3, 2008; accepted: January 4, 2009

## 1 Introduction

Polyphenols are secondary plant metabolites ubiquitously distributed in fruits and vegetables and are always present in a balanced, healthy diet. Fruit and vegetables have a health-promoting effect, but the mechanism of their protective action is not clearly understood. It has been suggested that polyphenols may be partially responsible for the beneficial effects and polyphenol activity has been studied in many cell culture and animal models. While polyphenols

are metabolized by gut bacteria and mammalian tissues, the effect of polyphenol metabolites has been studied much less. It is possible that some of their activities might actually be mediated by their metabolites in addition or in place of the original compound present in food. Russell *et al.* [1] have suggested that the microbiota metabolism of polyphenolic compounds determines the action of these compounds by inhibiting prostanoid production. Hydrocaffeic acid (HCAF), hydroferulic acid (HFER), and 3,4-dihydroxyphenyl acetic acid (dOHPA) are all polyphenol metabolites derived from the colon microbiota, which are found at high concentration in plasma, excreted urine, and fecal water after consumption of coffee or an omnivorous diet including fruits and vegetables [2, 3]. HCAF has potent antioxidant activity in endothelial cells [4], an anti-proliferative effect on cancer colon cells [5] and protects keratinocytes from UV irradiation, reducing the expression of IL-6 and IL-8 [6]. The polyphenol metabolite dOHPA has been studied in connection with dopamine metabolism [7], but not as

**Correspondence:** Dr. Mar Larrosa, Department of Pharmacology, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy  
**E-mail:** mar.larrosa@unifi.it  
**Fax:** +39-055-4271-280

**Abbreviations:** DSS, dextran sodium sulfate; IBD, inflammatory bowel disease; 8-oxodG, 8-oxo-2'-deoxyguanosine; ROS, reactive oxygen species

a colonic microbiota metabolite. Gao *et al.* [8] have demonstrated its anti-proliferative activity on colon cancer cell line HCT-116. The activity of HFER is still not documented.

Chronic inflammatory conditions are present in many human pathological processes, and it is possible that consumption of fruits and vegetables (and the associated polyphenols) might ameliorate inflammation [9–11]. Inflammatory bowel diseases (IBD) affect millions of individuals in the western world alone [12] and are influenced by environmental factors and diet. Although the etiology and pathogenesis of IBD is not yet clear, an imbalance of pro-inflammatory cytokines (TNF- $\alpha$ , IL-1, and IL-6) seem to play a important role in modulating inflammation [13] and therefore an anti-TNF- $\alpha$  antibody has been used in therapy [14].

The aim of the present study was to investigate the effects of polyphenol metabolites on inflammation in experimental cell and animal models. To study their activity on intestinal inflammation we used the rat colitis model after the administration of dextran sodium sulfate (DSS) p.o. which can induce a syndrome similar to IBD with diarrhea, rectal bleeding, weight loss, multiple erosions, abscesses [15], and variation in Th1 and Th2 cytokine profile [16].

## 2 Materials and methods

### 2.1 Chemicals

3-hydroxybenzoic acid (3OHB), 3,4-dihydroxybenzoic acid (3,4dOHB), 4-hydroxy-3-methoxybenzoic acid (OHMB), 4-hydroxy-3-methoxyphenylacetic acid (OHMPA), 3,4-dihydroxyphenylacetic acid (dOHPA), hydrocaffeic acid (HCAF), hydroferulic acid (HFER), and ferulic (FE) were from Fluka (Milan, Italy), 4-hydroxybenzoic acid (4OHB), phenylacetic acid (PA), 3-hydroxyphenylacetic acid (3OHPA), 4-hydroxyphenylacetic acid (4OHPA), hippuric acid (HIPU), 3-hydroxyhippuric acid (OHHIPU), 3-phenylpropionic acid (3PP), 3-hydroxyphenylpropionic acid (3OHPP), 4-hydroxyphenylpropionic acid (4OHPP), and hydrocinnamic acid-d<sub>9</sub> were purchased from Aldrich (Sigma, Milan, Italy). The compound 5-(3-hydroxyphenyl) valeric acid (OHPVAL) was synthesized by Professor Menichetti, Department of Organic Chemistry, University of Florence, Italy. Formic acid, ACN, and methanol were of LC-MS grade supplied by Merck (Darmstadt, Germany). DSS (Mw = 36 000–50 000) was from ICN Bio-medicals (Segrate, Milan, Italy). Nuclease P1, alkaline phosphatase, RNase, proteinase K, 2'-deoxyguanosine (dG), 8-oxo-2'-deoxyguanosine (8-oxodG), 2,4-dinitrophenylhydrazine (DNPH), and 1,1,3,3-tetraethoxypropane (TEP), indomethacin, and acetylsalicylic acid were purchased from Sigma (Sigma Chemical Co., Milan, Italy). EIA prostaglandin-kit was obtained from Cayman Chem (San Diego, CA, USA).

### 2.2 Anti-inflammatory *in vitro* screening assay

The CCD18-Co human colon fibroblast cell line (ATCC number CRL-1459) was grown in Eagle's MEM containing 2 mM glutamine, 0.1 mM non essential amino acids, 1 mM sodium pyruvate, 100 Units/mL penicillin, and 100 g/mL streptomycin and supplemented with 10% fetal bovine serum (FBS). The cell line was maintained at 37°C in a 95% oxygen 5% CO<sub>2</sub> atmosphere. Screening for anti-inflammatory activity was performed according to Salve-mini *et al.* [17] with modifications. Cells were seeded at 5000 cell/well in 96-well plates and after 24 h medium was replaced with fresh medium containing 0.1% FBS for another 24 h. Cells were then treated with different polyphenol metabolites (100  $\mu$ M) and co-stimulated with 1 ng/mL of IL-1 $\beta$  (Calbiochem, Milan, Italy) for 18 h. The medium was finally removed for PGE<sub>2</sub> assay and cells were fixed with methanol/acetic acid 3:1 v/v for crystal violet assay [18], in order to detect any cytotoxic effect of compounds. PGE<sub>2</sub> levels in cell media were measured using an immunoenzymatic method (EIA kit, Cayman Chem, San Diego, CA, USA) according to the manufacturer's specifications. A dilution of 1:50 was used.

### 2.3 Animals

Male Fischer 344 rats (175–200 g), male Wistar rats (200–250 g) were purchased from Nossan (Correzzana, Milan, Italy) and male Swiss albino mice (25–30 g) were from Morini (San Polo D'Enza, Reggio Emilia Italy). All the procedures adopted were carried out in agreement with the European Union Regulations on the Care and Use of Laboratory Animals (OJ of ECL 358/1, 12/18/1986) and the experiments were conducted according to Italian regulations on the protection of animals used for experimental and other scientific purposes (DM 116/1992).

### 2.4 Writhing test

The writhing test was performed according to Koster *et al.* [19]. Male Swiss albino mice (25–30 g) were injected i.p. with a 0.6% aqueous solution of acetic acid (10 mL/kg). The number of stretching movements was counted for 10 min, starting 6 min after acetic acid injection. Treatments (HCAF, dOHPA, and HFER) were administered i.p. at the dose of 30 mg/kg on the opposite abdominal side, 14 min before administration of the acetic acid solution. Indomethacin at 10 mg/kg and acetylsalicylic acid at 800 mg/kg were administered as anti-inflammatory positive controls. Animals were euthanized after the experiments.

### 2.5 Paw pressure test

The nociceptive threshold was determined with an analgesimeter (Ugo Basile, Varese, Italy) according to the method described by Leighton *et al.* [20]. Threshold pres-

sure was measured before and 30, 45, and 60 min after treatment. The pre-tested rats (male Wistar) which scored below 30 g or over 90 g were rejected. An arbitrary cut-off value of 160 g was adopted. To induce an inflammatory process in the rat, carrageenan (0.1 mL, 1%) was administered s.c. in one paw 4 h before each test. HCAF, dOHPA, and HFER were administered i.p. at 30 mg/kg 30, 45, and 60 min before performing the test. Animals were euthanized after the experiments.

## 2.6 Experimental diet and colitis induction

Fischer 344 4-wk old male rats were acclimatized for one week and then randomly divided into three experimental groups (6 rats *per* group). The control group was fed with a AIN 76 diet, prepared using components purchased from Piccioni (Gessate, Milan, Italy) and drinking water *ad libitum* for 18 days. Rats in the DSS group were fed as the control and received 4% DSS dissolved in drinking water *ad libitum* for 4 days; rats were sacrificed 4 days after completion of DSS administration (recovery time). The HCAF group received also the AIN 76 diet where 50 mg/kg/day of HCAF were added. A pre-treatment of 10 days with HCAF diet was done before initiation of 4% DSS treatment. When a 4-day 4% DSS treatment was initiated, HCAF diet was co-administered. After the end of DSS treatment, HCAF was administered for another 4 days (recovery time) and then the rats were sacrificed. Weight, health conditions, and water consumption of each rat was monitored every day. The Human Equivalent Dose (HED) for the administered dose of 50 mg/kg HCAF is 7.25 mg/kg HCAF for a human of 70 kg according to the formula:  $HED = \text{animal dose in mg/kg} \times (\text{animal weight in kg/human weight in kg})^{0.33}$  [21].

## 2.7 Fecal water content

Feces were immediately collected after deposition and then weighed and dried in a de-humidified oven at 65°C until there was no weight variation for 24 h. The percent of fecal water content was calculated as the difference between the wet and dry weights of the pellet and expressed as percentage.

## 2.8 Determination of HCAF in feces by LC-MS

Feces (0.3 g) of the 10<sup>th</sup> day of administration of test compounds were weighted and after adding 8 µg of hydrocinnamic acid-d<sub>9</sub> as internal standard, were homogenized with an Ultraturrax T-25 in 5 mL of water/HCl (99.9:0.1) and centrifuged at  $4.500 \times g$  *per* 5 min. Supernatant was acidified with HCl (0.2% final concentration v/v) and loaded onto a SPE 200 mg Strata C18-E cartridge (Phenomenex Italia, Bologna, Italy). Compounds were eluted with 1 mL of methanol and 20 µL were injected for analysis. The LC

system was a PerkinElmer Series 200 system (PerkinElmer, Italy) consisting of a binary-pump and autosampler. Samples were separated onto a RP C<sub>18</sub> Phenomenex Luna column (150 × 4.60 mm<sup>2</sup>, 5 µm particle size). The mobile phases were MS grade water (solvent A) and ACN/water 97:3 v/v (solvent B), both containing 0.1% formic acid, at a flow rate of 1 mL/min. The gradient started with 10% of B during 3 min to reach 80% B at 13 min, 80% B at 14 min, and 90% of B at 15 min; chromatographic run time was 30 min *per* injection. A mass spectrometer API 365 triple quadrupole was used for MS detection. The mass spectrometer was operated in negative-ion, multiple reaction monitoring (MRM) in negative ion mode. The temperature and flow rate of the turbo gas was adjusted to 250°C and 8 L/min, respectively. The ionization voltage was set to –4000 V. Nitrogen was used as curtain gas, nebulizing gas, and collision gas, with flow settings of 6, 7, and 3, respectively. Collision energy was 26 V. Singly charged precursor-product ion (MS/MS) transitions were monitored at  $m/z$  181 → 137, 181 → 59, for HCAF and 158 → 158 → 114 for hydrocinnamic acid-d<sub>9</sub> (internal standard). The dwell time was 200 ms for all compounds. For quantification, a standard curve of HCAF and internal standard was done in blank fecal samples. The percentage recovery was used to correct the concentrations in fecal samples.

## 2.9 RT-PCR

Total RNA was isolated from rat distal colon mucosa using the Rneasy midi kit (Qiagen, Milan, Italy). For first-strand cDNA synthesis 1 µg of RNA from each sample was reverse-transcribed using 100 Units RT superscript II and 1 × random hexamers (Roche, Monza, Italy). The PCR reaction was carried out on aliquots of the cDNA preparation for each gene as previously described [22]. The PCR products were separated onto 1.5% agarose gel w/v. The amplified products were photographed and the intensity of the bands was analyzed with Quantity-One software (Bio-Rad, Segrate, Milan, Italy). For each target gene the relative amount of mRNA was calculated in the sample using β-actin co-amplified as internal standard. Primer sequences for TNF-α and IFN-γ were from Bradesi *et al.* [23]. β-Actin and IL1-β were from Tsune *et al.* [24] COX-1 was from Vogliagis *et al.* [25] and IL-8 from Kim *et al.* [26].

## 2.10 PGE<sub>2</sub> assay

PGE<sub>2</sub> levels in distal colon mucosa homogenates were measured using an immunoenzymatic method (EIA kit, Cayman Chem, San Diego, CA, USA) according to the manufacturer's specifications. Samples of distal colon mucosa (10 mg) were homogenized in 1 mL of 0.1 M phosphate pH 7.4 containing 1mM EDTA and 10 µM indomethacin and centrifuged at  $9000 \times g$  *per* 20 min. A dilution of sample supernatant 1:50 was used.

### 2.11 Determination of 8-oxodG in DNA from colon mucosa

An oxidized form of guanine, 8-oxodG, is generated by reactive oxygen species (ROS) and is widely used as a marker of oxidative DNA damage [27]. DNA was isolated according to a standard published procedure [28] and aliquots of 100 µg of DNA were hydrolyzed with 10 µL of nuclease P1 (1100 Units/mL) for 2 h and 14 µL of alkaline phosphatase (750 Units/mL) for 30 min. The hydrolyzed mixture was filtered using Micropure-EZ enzyme remover (Amicon, Millipore, Milan, Italy) and 50 µg were injected into the HPLC for 8-oxodG determination. The nucleosides were separated with a C18 RP column (Supelco, Milan, Italy, 5 µm, ID 0.46 × 25 cm<sup>2</sup>). The levels of 8-oxodG were detected using an ESA Coulochem II electrochemical detector in line with a UV detector. The 8-oxodG levels were expressed as the ratio of 8-oxodG/dG × 10<sup>-6</sup>.

### 2.12 Malonyldialdehyde (MDA) levels in colonic tissue

MDA levels were determined according to the method of Mateos *et al.* [29] with some modifications. Colon tissue (30 mg) was homogenized in 500 µL of Trizma base buffer pH 7.4 containing 0.2 M sucrose and 5 mM DTT in an Ultraturrax T-25. Homogenate was centrifuged at 10000 × *g* for 30 min at 4°C and 250 µL of supernatant were submitted to alkaline hydrolysis with 50 µL of 6 M NaOH for 30 min at 60°C. Protein was then precipitated with 30% trichloroacetic acid followed by centrifugation at 2800 × *g* for 10 min. A volume of 250 µL supernatant was mixed with 25 µL of 5 mM DNPH and incubated for 30 min at room temperature, protected from light. The reaction mixture (200 µL) was injected into an HPLC equipped with an LC-10 AD Shimadzu pump, a UV–Vis Perkin Elmer LC 290 detector and with a Water Spherisorb ODS-2 column (4.6 × 150 mm<sup>2</sup> ID, 5 µm particle size).


### 2.13 Statistical analysis

All analyses were carried out using SPSS® 14.0 software. All data were expressed as the mean ± SD of independent measurements. Statistical significance was determined by Student's *t*-test or by one-way ANOVA analysis, using *p* < 0.05 as the level of significance.

## 3 Results

### 3.1 *In vitro* screening anti-inflammatory activity of polyphenol metabolites

On the basis of the work of Déprez *et al.* [30], Gonthier *et al.* [31], and Rios *et al.* [32], we selected 18 polyphenol metabolites for screening. To avoid interference by growth



**Figure 1.** Dose-response effect of HCAF (■), HFER (▨), and dOHPA (□) on PGE<sub>2</sub> production by CCD18 cells stimulated with 1 ng/mL of IL-1β for 18 h. Data shown are mean ± SD, *n* = 3.

inhibition or cytotoxic effects, we checked cell growth and cytotoxicity with the crystal violet assay at the end of the experiment. We used a concentration of 100 µM of each compound and an incubation time of 24 h. None of the metabolites tested, affected growth or cytotoxicity (data not shown). From all tested compounds, the metabolites that significantly inhibited (*p* < 0.05) PGE<sub>2</sub> production were dOHPA, 3OH-HIPU, 3OHPP, 4OHPP, HCAF, FER, and HFER (see Table 1). Metabolites that inhibited PGE<sub>2</sub> production (HCAF, HFER, and dOHPA) more than 50% were used to do a dose-response curve (0.1–100 µM) (Fig. 1).







### 3.2 Anti-inflammatory effects on the writhing test

The three selected polyphenol metabolites (HCAF, HFER, and dOHPA) administered i.p. at a dose of 30 mg/kg caused a significant decrease (*p* < 0.05) in the number of abdominal contractions (writhings) induced by diluted acetic acid administration i.p. in mice, a classic test of anti-nociceptive and anti-inflammatory activity (Table 2). The number of writhings was reduced by 27, 35, and 40% by HFER, HCAF, and dOHPA, respectively. Common anti-inflammatory drugs (indomethacin and sodium salicylate) were used as positive controls.

### 3.3 Effect on carrageenan-induced hyperalgesia in rats

Carrageenan-induced hyperalgesia is another classic test for measuring the activity of anti-inflammatory analgesic compounds. The maximum effect of the compounds tested was observed 45 min after the subcutaneous administration of 30 mg/kg of HCAF, HFER, and dOHPA. As shown in Table 3, HCAF, HFER, and dOHPA significantly increased the tolerance to the applied pressure of the inflamed paw. HCAF was the most potent of the polyphenol metabolites tested.

**Table 1.** Percentage of inhibition in PGE<sub>2</sub> production by polyphenol metabolites


Polyphenol metabolites (100 $\mu$ M)		Percentage inhibition in PGE <sub>2</sub> production
3-Hydroxybenzoic acid (3OHB) R1=H; R2=OH; R3=H		9 (6, 14)
4-Hydroxybenzoic acid (4OHB) R1=H; R2=H; R3=OH		8 (6, 11)
3,4-Dihydroxybenzoic acid (protocatechuic acid, 3,4dOHB) R1=H; R2=OH; R3=OH		17 (3, 31)
4-Hydroxy-3-methoxybenzoic acid (vanillic acid, OHMB) R1=H; R2=OCH <sub>3</sub> ; R3=OH		7 (4, 10)
Phenylacetic acid (PA) 3-Hydroxyphenylacetic acid (3OHPA) R1=H; R2=OH; R3=H		16 (7, 26)
4-Hydroxyphenylacetic acid (4OHPA) R1=H; R2=H; R3=OH		3 (0, 8)
3,4-Dihydroxyphenylacetic acid (homoprotocatechuic acid, dOHPA) R1=H; R2=OH; R3=OH		0 (–5, 0)
4-Hydroxy-3-methoxyphenylacetic acid (homovanillic acid, 4OHMPA) R1=H; R2=OCH <sub>3</sub> ; R3=OH		61 (50, 73) <sup>a)</sup>
Hippuric acid (HIPU) 3-Hydroxyhippuric acid (3OHHIPU) R1=H; R2=OH; R3=H		0 (–11, 6)
		34 (29, 38) <sup>a)</sup>
3-Phenylpropionic acid (3PP) 3-Hydroxyphenylpropionic acid (phloretic acid, 3OHPP) R1=H; R2=OH; R3=H		21 (8, 37)
4-Hydroxyphenylpropionic acid (hydrocinnamic acid, 4OHPP) R1=H; R2=H; R3=OH		41 (35, 49) <sup>a)</sup>
3,4-Dihydroxyphenylpropionic acid (hydrocaffeic acid, HCAF) R1=H; R2=OH; R3=OH		33 (26, 44) <sup>a)</sup>
3-(4-Hydroxy-3-methoxyphenyl) propionic acid (hydroferulic acid, HFER) R1=H; R2=OCH <sub>3</sub> ; R3=OH		94 (92, 95) <sup>a)</sup>
		35 (25, 45) <sup>a)</sup>
<i>trans</i> -4-Hydroxy-3-methoxycinnamic acid (ferulic acid, FER)		71 (63, 77) <sup>a)</sup>
5-(3-hydroxyphenyl)valeric acid (OHPVAL)		9 (2, 16)

a) Significant *versus* control  $p < 0.05$   $n = 3$ . Values are mean followed by smaller and greater value.

### 3.4 Effect of HCAF on DSS colonic inflammation

Control and DSS-treated rats did not vary their water intake ( $17.5 \pm 4.5$  mL,  $17.1 \pm 3.6$  mL, and  $15.9 \pm 1.6$  mL, in control, DSS, and HCAF groups, respectively) during DSS administration in our experimental protocol. Nevertheless,

DSS induced a significant reduction in body weight and increased fecal water content, indicating the presence of colitis in these animals. Body weight gain media was  $20.6 \pm 7.2$  g for control rats, which decreased to  $3.8 \pm 4.8$  g for DSS group. HCAF at 50 mg/kg counteracted this effect



**Figure 2.** Expression of IL-1 $\beta$  (A), IFN- $\gamma$  (B), TNF- $\alpha$  (C), and IL-8 (D) measured by RT-PCR in distal colon mucosa of control, DSS, and DSS-HCAF treated rats (upper lines in 2A and 2D, lower lines 2B and 2C).  $\beta$ -actin co-amplified as internal standard (a) significantly different from control group, (b) significantly different from DSS treated group.  $n = 6$ . Arbitrary units.

**Table 2.** Effect of dOHPA, HCAF, and HFER on mouse-writhing test

Treatment	$n$ mice	$n$ Abdominal constrictions
Saline	10	46.4 $\pm$ 2.2
dOHPA 30 mg/kg	10	27.4 $\pm$ 1.9 <sup>a</sup>
HCAF 30 mg/kg	10	30.3 $\pm$ 1.5 <sup>a</sup>
HFER 30 mg/kg	10	34.0 $\pm$ 2.1 <sup>a</sup>
Acetylsalicylic acid 800 mg/kg	10	18.1 $\pm$ 3.3 <sup>a</sup>
Indomethacin 10 mg/kg	10	13.7 $\pm$ 2.4 <sup>a</sup>

a)  $p < 0.05$  versus saline-treated mice.  $n = 10$ .

and rats belonging to HCAF group had a body weight gain of  $10.3 \pm 1.2$  g. Fecal water content increased from  $28.1 \pm 6.7\%$  (control value) to  $56 \pm 1.1\%$  upon DSS treatment. This increase was prevented by HCAF treatment ( $28.6 \pm 2.8\%$ ).

Using RT-PCR, we measured the level of expression of classical inflammation mediators (IL-1 $\beta$ , IFN- $\gamma$ , TNF- $\alpha$ , and IL-8 cytokines) in the distal colonic mucosa of these animals. DSS induced a significant increase ( $p < 0.05$ ) in IL-1 $\beta$ , IFN- $\gamma$ , TNF- $\alpha$ , and IL-8 in the colonic mucosa (Fig. 2A–D). Treatment with HCAF significantly reduced the expression of all these cytokines ( $p < 0.05$ ) except IFN- $\gamma$ . We also observed an increase in COX-2 expression, but HCAF treatment did not vary with this parameter (Fig. 3B). COX-1 expression was down-regulated by DSS and simi-

larly not influenced by HCAF (Fig. 3A). Also PGE<sub>2</sub> mucosal levels were increased by DSS from  $500 \pm 89$  (control levels) to  $3590 \pm 1019$  but did not vary significantly after HCAF treatment ( $5297 \pm 1796$ ) (mean  $\pm$  SD).


Treatment with DSS increased by three-fold the levels of lipid peroxidation measured as MDA levels in the colon mucosa (Table 4). MDA levels were significantly attenuated by HCAF treatment. As shown in Table 4, oxidized DNA levels measured as the ratio of 8-oxodG to dG  $\times 10^{-6}$ , were higher in the mucosa of rats treated with DSS ( $p < 0.001$ ). HCAF was able to inhibit DNA oxidation damage induced by DSS ( $p < 0.001$ ).

### 3.5 HCAF content in feces

Feces of the 10<sup>th</sup> day after 50 mg/kg HCAF ingestion were analyzed by LC-MS/MS. HCAF content in feces, after feeding for 10 days, was very homogenous varying between 4.5 and 5.5  $\mu$ M in individual animals. The analysis of feces showed the presence of the [M–H]<sup>–</sup> ion corresponding to the ingested compound HCAF ( $m/z$  181) that produced two daughter ions at  $m/z$  139 and 59 (Fig. 4). No HCAF was found in control feces.

## 4 Discussion

Our results demonstrate that some microbiota-derived polyphenol metabolites, found in fecal water of humans con-



**Figure 3.** COX-1 (A) and COX-2 (B) expression measured by RT-PCR in distal colon mucosa of control, DSS, and DSS-HCAF treated rats.  $\beta$ -actin co-amplified as internal standard (lower lines) (a) significantly different from control group, (b) significantly different from DSS treated group  $p < 0.05$   $n = 6$ . Arbitrary units.

suming a balanced diet [3], have an anti-inflammatory action in different inflammation models.

Anti-inflammatory effects are documented in the literature for some polyphenols and derivatives as caffeic acid phenethyl ester [33, 34] and ferulic acid, a possible precursor of HFER, that inhibits macrophage inflammatory protein-2 (MIP-2) and TNF- $\alpha$  levels in macrophages stimulated with LPS [35]. Ferulic acid derivatives have also been shown to have suppressive effect on COX-2 promoter activity on human colon DLD-1 cancer cells [36] and ferulic acid dimer inhibits COX-2 expression in LPS stimulated macrophages [37].

The screening of 18 polyphenol metabolites presented in this paper show that eight of them were able to decrease PGE<sub>2</sub> production *in vitro*. This is the first time that an anti-inflammatory effect has been attributed to many of these compounds. The dose-effect curve done for HCAF showed that even at low dose (0.1  $\mu$ M) it exerted a potent effect on PGE<sub>2</sub> production inhibition. The 0.1  $\mu$ M concentration is not so far from the real levels that HCAF reaches in human

**Table 3.** Effect of HFER, HCAF, and dOHPA on hyperalgesia induced by carrageenan in rat paw pressure test. I.p. injection of 1% carrageenan was performed 3 h before test. Compounds were administered 45 min before test

Treatment	Paw pressure (g)	
	Pre-test	45 min
Saline	72.0 $\pm$ 1.5	23.5 $\pm$ 3.0
HFER 30 mg/kg	72.0 $\pm$ 1.7	45.5 $\pm$ 1.8 <sup>a)</sup>
HCAF 30 mg/kg	72.0 $\pm$ 2.2	54.0 $\pm$ 1.9 <sup>a)</sup>
dOHPA 30 mg/kg	70.0 $\pm$ 3.2	46.5 $\pm$ 1.5 <sup>a)</sup>
Indomethacin 10 mg/kg	69.5 $\pm$ 3.1	55.3 $\pm$ 4 <sup>a)</sup>

a)  $p < 0.05$  versus Carrageenan-treated rats.  $n = 4$ .

**Table 4.** MDA levels expressed as nmol MDA/mg protein and oxidative DNA damage measured as the ratio of 8-oxodG to dG  $\times 10^{-6}$  in the colon of control, DSS-, and DSS-HCAF-treated rats

	MDA levels (nmol/mg protein)	8-OxodG $\times 10^{-6}$ dG
CONTROL	1.17 $\pm$ 0.42 <sup>a)</sup>	2.06 $\pm$ 0.62 <sup>a)</sup>
DSS	3.45 $\pm$ 0.72 <sup>b)</sup>	9.74 $\pm$ 2.18 <sup>b)</sup>
HCAF 50 mg/kg	1.26 $\pm$ 0.55 <sup>b)</sup>	2.06 $\pm$ 0.62 <sup>a, b)</sup>

$p < 0.05$  for MDA determination and  $p < 0.01$  for DNA damage  $n = 6$ .


a) Significantly different from DSS-treated groups.

b) Significantly different from control group.

plasma (66 nM) after the ingestion of 55 g of cooked artichoke [38].

Of the eight compounds having *in vitro* activity we selected three (HCAF, dOHPA, and HFER) for further *in vivo* testing. When they were administered intra-peritoneally at 30 mg/kg they all decreased the number of abdominal constrictions and increased the weight tolerance in the paw-pressure test, indicating systemic anti-inflammatory action. Our observations are in agreement with previous data on related compounds. For example, vanillic acid has inhibitory activity in arachidonic acid-induced ear edema and in the writhing test [39]. Chlorogenic acid (one of the nutritional precursor of these compounds) inhibits carrageenin-induced paw edema and also the number of flinches during the late phase in the formalin-induced pain test [40].

Of the three compounds with *in vivo* anti-inflammatory activity, we selected HCAF for *in vivo* testing on colitis in rats. The levels of HCAF in rat feces detected after oral administration of 50 mg/kg of HCAF acid were similar to those found (5.2  $\mu$ M) in human fecal water content when subjects followed a diet without restrictions [3]. The low quantity of HCAF found in feces of rats fed with 50 mg/kg is probably due to the fact that HCAF is mainly absorbed in the stomach or the upper part of the small intestine [41] and



**Figure 4.** Chromatogram of MS2 (negative ion mode) of HCAF found in feces collected after 10 days of 50 mg/kg HCAF administration. Arrows indicate daughter ions.

only a small part of the administered HCAF reaches the colon.

After HCAF administration the colonic inflammation induced by DSS was clearly inhibited. In fact, HCAF considerably decreased both body weight loss and stool water content after DSS administration. When the cytokine profile was studied, we found that IL-1 $\beta$  and TNF- $\alpha$  mRNA levels were increased by DSS. These cytokines are elevated during colonic inflammation, mainly in the lamina propria containing mononuclear cells [42]. Treatment with HCAF seemed able to down-regulate the expression of both cytokines. These results are in agreement with previous data showing down-regulation of these cytokines in rats fed with phytosteryl ferulates, a possible precursor of HCAF [43]. IL-8 is up-regulated in patients with ulcerative colitis [44] and has been correlated with colorectal carcinogenesis [45]. In our experiments IL-8 was decreased by HCAF treatment almost to control levels. Similar effects of HCAF have been observed in human keratinocytes after UV exposure [8].

Although COX-1 is a constitutively expressed enzyme, its expression in the DSS group was significantly decreased and HCAF treatment was not able to reverse this effect. This might be explained by erosion of the crypt epithelium where this enzyme is located. Similar observations were obtained by Tessner *et al.* [46] and Martin *et al.* [47]. COX-2 expression was increased in DSS but HCAF did not correct this overexpression. This might explain why PGE<sub>2</sub> levels, increased by DSS, were not reduced by HCAF. In contrast, in our *in vitro* experiments, HCAF inhibited the production of PGE<sub>2</sub>, an effect that was not observed in the colonic mucosa inflamed after DSS. In these different *in vitro* and *in vivo* models, inflammation is probably regulated by different mediators and pathways. We suggest that HCAF inhibits leukotriene biosynthesis since hydroxyeicosatetraenoic acids (HETEs) enhance IL-1 mediated COX-2 expression in human colonic myofibroblasts [48] and caffeic acid is a 5-lipoxygenase inhibitor [49]. However, we have no direct data on the activity of HCAF on these pathways.

Surprisingly the anti-inflammatory effect of HCAF on DSS colitis was not mediated by inhibition in PGE<sub>2</sub> produc-

tion. This requires further investigation since *in vitro* HCAF clearly inhibited PGE<sub>2</sub> production. The inherent complexity of physiological conditions *in vivo* including food matrix interactions could be involved in this apparent contradiction. The role of PGE<sub>2</sub> in colon inflammation is controversial. Whereas inhibition in PGE<sub>2</sub> production is generally considered beneficial in inflammation control [50], exogenously applied PGE<sub>2</sub> reduces mucosal inflammatory cytokines and epithelial erosion after DSS [51, 46]. Moreover, endogenous PGE<sub>2</sub> heals small intestinal lesions [52] and the application of EP4 (a stimulator of PGE<sub>2</sub> receptor), suppresses DSS induced colitis [53]. It is also known that gastric and colonic lesions are induced by COX-1 and COX-2 inhibitors [54, 55]. Therefore, it is possible that anti-inflammatory activity on the colon can be exerted through routes not involving the down-regulation of COX-2 or a decrease in PGE<sub>2</sub> concentration in the colonic mucosa. For instance, caffeic acid has shown a protective effect down-regulating iNOS expression via inhibition in NF- $\kappa$ B activation in neuroinflammation [56].

ROS are also important mediators in colonic inflammation [57] where the antioxidant status is compromised [58]. ROS induces the oxidation of proteins, lipids, and DNA [59, 60]. Guanine is the most easily oxidized base in DNA, having the lowest oxidation potential of the four canonical bases [61]. An oxidized form of guanine is 8-oxodG that is generated by ROS and is widely used as a marker of oxidative DNA damage [27, 62]. DSS treatment enhances ROS levels [63] and free radicals induce oxidative DNA damage in colonic mucosa [64]. Our results show that DSS increased the lipid peroxidation level, measured as MDA and oxidized DNA (as ratio 8-oxodG/dG). Increased oxidation damage and lipid peroxidation were diminished by HCAF treatment, either by direct antioxidant activity or by its ability to increase eNOS expression and activity [4].

In conclusion, this study demonstrates that metabolites derived from polyphenols (HCAF, dOHPA, and HFER) through the metabolism of colon microbiota, are able to inhibit inflammation. HCAF inhibits DSS-induced colitis lipid peroxidation and DNA damage in colon mucosa, down-regulating fundamental cytokines involved in the inflammatory process (TNF- $\alpha$ , IL-1 $\beta$ , and IL-8).



Our results suggest that foods containing significant HCAF precursors (procyanidins, hydroxycinnamic acid derivatives, *etc.*) such as artichoke, cocoa, apples, strawberries, *etc.*, could exert anti-inflammatory activity and reduce intestinal inflammation in humans. If these observations are confirmed in clinical trials, polyphenol-rich foods or phenolic acid supplements may have potential therapeutic and/or preventive applications in IBD.

*This research has been supported by a post-doctoral fellowship of the Spanish Ministry of Science and Innovation (to Mar Larrosa), by Nugo (FP6-506360) and Flavo (2005-513960) programs of the EU Community, by grants of MIUR (Italy) and by the University of Florence, Italy. We thank to Mary Forrest for revision of the manuscript.*

*The authors have declared no conflict on interest.*

## 5 References

- [1] Russell, W.-R., Labat, A., Scobbie, L., Duncan, S.-H., Availability of blueberry phenolics for microbial metabolism in the colon and the potential inflammatory implications, *Mol. Nutr. Food Res.* 2007, 51, 726–731.
- [2] Monteiro, M., Farah, A., Perrone, D., Trugo, L.-C., Donangelo, C., Chlorogenic acid compounds from coffee are differentially absorbed and metabolized in humans, *J. Nutr.* 2007, 137, 2196–2201.
- [3] Jenner, A.-M., Rafter, J., Halliwell, B., Human fecal water content of phenolics: the extent of colonic exposure to aromatic compounds, *Free Radic. Biol. Med.* 2005, 15, 38, 763–772.
- [4] Huang, J., de Paulis, T., May, J.-M., Antioxidant effects of dihydrocaffeic acid in human EA.hy926 endothelial cells, *J. Nutr. Biochem.* 2004, 15, 722–729.
- [5] Karlsson, P.-C., Huss, U., Jenner, A., Halliwell, B., *et al.*, Human fecal water inhibits COX-2 in colonic HT-29 cells: role of phenolic compounds, *J. Nutr.* 2005, 135, 2343–2349.
- [6] Poquet, L., Clifford, M.-N., Williamson, G., Effect of dihydrocaffeic acid on UV irradiation of human keratinocyte HaCaT cells, *Arch. Biochem. Biophys.* 2008, 476, 196–204.
- [7] Nunes, C., Almeida, L., Laranjinha, J., 3,4-Dihydroxyphenylacetic acid (DOPAC) modulates the toxicity induced by nitric oxide in PC-12 cells via mitochondrial dysfunctioning, *Neurotoxicology* 2008, 29, 998–1007.
- [8] Gao, K., Xu, A., Krul, C., Venema, K., *et al.*, Of the major phenolic acids formed during human microbial fermentation of tea, citrus, and soy flavonoid supplements, only 3,4-dihydroxyphenylacetic acid has antiproliferative activity, *J. Nutr.* 2006, 136, 52–57.
- [9] Sacanella, E., Vázquez-Agell, M., Mena, M.-P., Antúnez, E., *et al.*, Down-regulation of adhesion molecules and other inflammatory biomarkers after moderate wine consumption in healthy women: a randomized trial, *Am. J. Clin. Nutr.* 2007, 86, 1463–1469.
- [10] Chun, O.-K., Chung, S.-J., Claycombe, K.-J., Song, W.-O., Serum C-reactive protein concentrations are inversely associated with dietary flavonoid intake in U.S. adults, *J. Nutr.* 2008, 138, 753–760.
- [11] Kauss, T., Moynet, D., Rambert, J., Al-Kharat, A., *et al.*, Rutoside decreases human macrophage-derived inflammatory mediators and improves clinical signs in adjuvant-induced arthritis, *Arthritis Res. Ther.* 2008, 10, R19.
- [12] Baumgart, D.-C., Carding, S.-R., Inflammatory bowel disease: cause and immunobiology, *Lancet*, 2007, 369, 1627–1640.
- [13] Ardizzone, S., Porro, B.-G., Biologic therapy for inflammatory bowel disease, *Drugs*, 2005, 65, 2253–2286.
- [14] Kuhbacher, T., Fölsch, U.-R., Practical guidelines for the treatment of inflammatory bowel disease, *World J. Gastroenterol.* 2007, 13, 1149–1155.
- [15] Okayasu, I., Hatakeyama, S., Yamada, M., Ohkusa, T., *et al.*, A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice, *Gastroenterology* 1990, 98, 694–702.
- [16] Dieleman, L.-A., Palmen, M.-J., Akol, H., Bloemena, E., *et al.*, Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines, *Clin. Exp. Immunol.* 1998, 114, 385–391.
- [17] Salvemini, D., Misko, T. P., Masferrer, J. L., Seibert, K., *et al.*, Nitric oxide activates cyclooxygenase enzymes, *Proc. Natl. Acad. Sci. USA* 1993, 90, 7240–7244.
- [18] Wolter, F., Akoglu, B., Clausnitzer, A., Stein, J., Downregulation of the cyclin D1/Cdk4 complex occurs during resveratrol-induced cell cycle arrest in colon cancer cell lines, *J. Nutr.* 2001, 131, 2197–220.
- [19] Koster, R., Anderson, M., de Beer, E. J., Acetic acid for analgesic screening, *Fed. Proc.* 1959, 18, 412–418.
- [20] Leighton, G.-E., Rodriguez, R.-E., Hill, R.-G., Hughes, J., K-opioid agonists produce antinociception after i.v. and i.c.v. but not intrathecal administration in the rat, *Br. J. Pharmacol.* 1988, 93, 553–560.
- [21] Reagan-Shaw, S., Nihal, M., Ahmad, N., Dose translation from animal to human studies revisited, *Faseb J.* 2008, 22, 659–661.
- [22] Guglielmi, F., Luceri, C., Giovannelli, L., Dolara, P., Lodovici, M., Effect of 4-coumaric and 3,4-dihydroxybenzoic acid on oxidative DNA damage in rat colonic mucosa, *Br. J. Nutr.* 2003, 89, 581–587.
- [23] Bradesi, S., Schwetz, I., Ennes, H.-S., Lamy, C.-M., *et al.*, Repeated exposure to water avoidance stress in rats: a new model for sustained visceral hyperalgesia, *Am. J. Physiol. Gastrointest. Liver Physiol.* 2005, 289, G42–53.
- [24] Tsune, I., Ikejima, K., Hirose, M., Yoshikawa, M., *et al.*, Dietary glycine prevents chemical-induced experimental colitis in the rat, *Gastroenterology* 2003, 125, 775–785.
- [25] Vogiagis, D., Glare, E.-M., Misajon, A., Brown, W., O'Brien, P.-E., Cyclooxygenase-1 and an alternatively spliced mRNA in the rat stomach: effects of aging and ulcers, *Am. J. Physiol. Gastrointest. Liver Physiol.* 2000, 278, G820–827.
- [26] Kim, H.-Y., Kang, Y.-J., Song, I.-H., Choi, H.-C., Kim, H.-S., Upregulation of interleukin-8/CXCL8 in vascular smooth muscle cells from spontaneously hypertensive rats, *Hypertens. Res.* 2008, 31, 515–523.
- [27] Cheng, K.-C., Cahill, D.-S., Kasai, H., Nishimura, S., Loeb, L.-A., 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G-T and A-C substitutions, *J. Biol. Chem.* 1992, 267, 166–172.
- [28] Lodovici, M., Casalini, C., Briani, C., Dolara, P., Oxidative liver DNA damage in rats treated with pesticide mixtures, *Toxicology* 1997, 117, 55–60.

- [29] Mateos, R., Lecumberri, E., Ramos, S., Goya, L., Bravo, L., Determination of malondialdehyde (MDA) by high-performance liquid chromatography in serum and liver as a biomarker for oxidative stress. Application to a rat model for hypercholesterolemia and evaluation of the effect of diets rich in phenolic antioxidants from fruits, *J. Chromatogr., B* 2005, **827**, 76–82.
- [30] Déprez, S., Brezillon, C., Rabot, S., Philippe, C., *et al.*, Polymeric proanthocyanidins are catabolized by human colonic microbiota into low-molecular-weight phenolic acids, *J. Nutr.* 2000, **130**, 2733–2738.
- [31] Gonthier, M.-P., Cheynier, V., Donovan, J.-L., Manach, C., *et al.*, Microbial aromatic acid metabolites formed in the gut account for a major fraction of the polyphenols excreted in urine of rats fed red wine polyphenols, *J. Nutr.* 2003, **133**, 461–467.
- [32] Rios, L.-Y., Gonthier, M.-P., Rémésy, C., Mila, I., *et al.*, Chocolate intake increases urinary excretion of polyphenol-derived phenolic acids in healthy human subjects, *Am. J. Clin. Nutr.* 2003, **77**, 912–918.
- [33] Khan, M., Elango, C., Ansari, M. A., Singh, I., Singh, A.-K., Caffeic acid phenethyl ester reduces neurovascular inflammation and protects rat brain following transient focal cerebral ischemia, *J. Neurochem.* 2007, **102**, 365–377.
- [34] Celik, S., Erdogan, S., Caffeic acid phenethyl ester (CAPE) protects brain against oxidative stress and inflammation induced by diabetes in rats, *Mol. Cell. Biochem.* 2008, **312**, 39–46.
- [35] Sakai, S., Ochiai, H., Nakajima, K., Terasawa, K., Inhibitory effect of ferulic acid on macrophage inflammatory protein-2 production in a murine macrophage cell line, Raw 264.7, *Cytokine* 1997, **4**, 242–248.
- [36] Hosoda, A., Ozaki, Y., Kashiwada, A., Mutoh, M., *et al.*, Syntheses of ferulic acid derivatives and their suppressive effects on cyclooxygenase-2 promoter activity, *Bioorg. Med. Chem.* 2002, **10**, 1189–1196.
- [37] Hirata, A., Murakami, Y., Atsumi, T., Shoji, M., *et al.*, Ferulic acid dimer inhibits lipopolysaccharide-stimulated cyclooxygenase-2 expression in macrophages, *In Vivo* 2005, **19**, 849–853.
- [38] Azzini, E., Bugianesi, R., Romano, F., Di Venere, D., *et al.*, Absorption and metabolism of bioactive molecules after oral consumption of cooked edible heads of *Cynara scolymus* L. (cultivar Violetto di Provenza) in human subjects: a pilot study, *Br. J. Nutr.* 2007, **97**, 963–9.
- [39] Lee, J.-Y., Jang, Y.-W., Kang, H.-S., Moon, H., *et al.*, Anti-inflammatory action of phenolic compounds from *Gastrodia elata* root, *Arch. Pharm. Res.* 2006, **29**, 849–858.
- [40] dos Santos, M.-D., Almeida, M.-C., Lopes, N.-P., de Souza, G.-E., Evaluation of the anti-inflammatory, analgesic and antipyretic activities of the natural polyphenol chlorogenic acid, *Biol. Pharm. Bull.* 2006, **29**, 2236–2240.
- [41] Poquet, L., Clifford, M. N., Williamson, G., Investigation of the metabolic fate of dihydrocaffeic acid, *Biochem. Pharmacol.* 2008, **75**, 1218–1229.
- [42] Reinecker, H. C., Steffen, M., Witthoeft, T., Pflueger, I., *et al.*, Enhanced secretion of tumour necrosis factor- $\alpha$ , IL-6, and IL-1  $\beta$  by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease, *Clin. Exp. Immunol.* 1993, **94**, 174–181.
- [43] Islam, M.-S., Murata, T., Fujisawa, M., Nagasaka, R., *et al.*, Anti-inflammatory effects of phytosteryl ferulates in colitis induced by dextran sulphate sodium in mice, *Br. J. Pharmacol.* 2008, **154**, 812–824.
- [44] Keshavarzian, A., Fusunyan, R.-D., Jacyno, M., Winship, D., *et al.*, Increased interleukin-8 (IL-8) in rectal dialysate from patients with ulcerative colitis: evidence for a biological role for IL-8 in inflammation of the colon, *Am. J. Gastroenterol.* 1999, **94**, 704–712.
- [45] Rubie, C., Frick, V.-O., Pfeil, S., Wagner, M., *et al.*, Correlation of IL-8 with induction, progression and metastatic potential of colorectal cancer, *World J. Gastroenterol.* 2007, **13**, 4996–5002.
- [46] Tessner, T.-G., Cohn, S.-M., Schloemann, S., Stenson, W.-F., Prostaglandins prevent decreased epithelial cell proliferation associated with dextran sodium sulphate injury in mice, *Gastroenterology* 1998, **115**, 874–882.
- [47] Martín, A.-R., Villegas, I., Alarcón de la Lastra, C., The COX-2 inhibitor, rofecoxib, ameliorates dextran sulphate sodium induced colitis in mice, *Inflamm. Res.* 2005, **54**, 145–151.
- [48] Di Mari, J.-F., Saada, J.-I., Mifflin, R.-C., Valentich, J.-D., Powell, D.-W., HETEs enhance IL-1-mediated COX-2 expression via augmentation of message stability in human colonic myofibroblasts, *Am. J. Physiol. Gastrointest. Liver Physiol.* 2007, **293**, G719–728.
- [49] Koshihara, Y., Neichi, T., Murota, S., Lao, A., *et al.*, Caffeic acid is selective inhibitor for leukotriene biosynthesis, *Biochim. Biophys. Acta* 1984, **792**, 92–97.
- [50] Vane, J.-R., Towards a better aspirin, *Nature* 1994, **367**, 215–216.
- [51] Sasaki, S., Hirata, I., Maemura, K., Hamamoto, N., *et al.*, Prostaglandin E2 inhibits lesion formation in dextran sodium sulphate-induced colitis in rats and reduces the levels of mucosal inflammatory cytokines, *Scand. J. Immunol.* 2000, **51**, 23–28.
- [52] Hatazawa, R., Ohno, R., Tanigami, M., Tanaka, A., Takeuchi, K., Roles of endogenous prostaglandins and cyclooxygenase isozymes in healing of indomethacin-induced small intestinal lesions in rats, *J. Pharmacol. Exp. Ther.* 2006, **318**, 691–699.
- [53] Nitta, M., Hirata, I., Toshina, K., Murano, M., *et al.*, Expression of the EP4 prostaglandin E2 receptor subtype with rat dextran sodium sulphate colitis: colitis suppression by a selective agonist, ONO-AE1-329, *Scand. J. Immunol.* 2002, **56**, 66–75.
- [54] Takeeda, M., Hayashi, Y., Yamato, M., Murakami, M., Takeuchi, K., Roles of endogenous prostaglandins and cyclooxygenase isoenzymes in mucosal defense of inflamed rat stomach, *J. Physiol. Pharmacol.* 2004, **55**, 193–205.
- [55] Okayama, M., Hayashi, S., Aoi, Y., Nishio, H., *et al.*, Aggravation by selective COX-1 and COX-2 inhibitors of dextran sulfate sodium (DSS)-induced colon lesions in rats, *Dig. Dis. Sci.* 2007, **52**, 2095–2103.
- [56] Jatana, M., Giri, S., Ansari, M.-A., Elango, C., *et al.*, Inhibition of NF- $\kappa$ B activation by 5-lipoxygenase inhibitors protects brain against injury in a rat model of focal cerebral ischemia, *J. Neuroinflamm.* 2006, **11**, 3–12.
- [57] Rózgá, J., The role of reactive oxygen metabolites in the pathogenesis of ulcerative colitis: a speculative synthesis, *Mater. Med. Pol.* 1989, **21**, 263–268.
- [58] Buffinton, G.-D., Doe, W.-F., Altered ascorbic acid status in the mucosa from inflammatory bowel disease patients, *Free Radic. Res.* 1995, **22**, 131–143.
- [59] Guptasarma, P., Balasubramanian, D., Matsugo, S., Saito, I., Hydroxyl radical mediated damage to proteins, with special reference to crystallines, *Biochemistry* 1992, **31**, 4296–4303.

- [60] Nishigori, C., Hattori, Y., Toyokuni, S., Role of reactive oxygen species in skin carcinogenesis, *Antioxid. Redox Signal.* 2004, 6, 561–570.
- [61] Steeken, S., Jovanovic, S., How easily oxidizable is DNA? One-electron reduction potentials of adenosine and guanosine radicals in aqueous solution, *J. Am. Chem. Soc.* 1997, 119, 617–618.
- [62] Wei, H.-C., Cai, Q. Y., Rahn, R., Zhang, X.-S., Singlet oxygen involvement in ultraviolet (254 nm) radiation-induced formation of 8-hydroxy-deoxyguanosine in DNA, *Free Radic. Biol. Med.* 1997, 23, 148–154.
- [63] Blackburn, A.-C., Doe, W.-F., Buffinton, G.-D., Salicylate hydroxylation as an indicator of hydroxyl radical generation in dextran sulfate-induced colitis, *Free Radic. Biol. Med.* 1998, 25, 305–313.
- [64] Tardieu, D., Jaeg, J.-P., Cadet, J., Embvani, E., *et al.*, Dextran sulfate enhances the level of an oxidative DNA damage biomarker, 8-oxo-7,8-dihydro-2'-deoxyguanosine, in rat colonic mucosa, *Cancer Lett.* 1998, 134, 1–5.